Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab

NARecruitingINTERVENTIONAL
Enrollment

796

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

March 31, 2035

Study Completion Date

March 31, 2037

Conditions
Recurrent Pregnancy LossEuthyroid With Thyroid Antibodies
Interventions
DRUG

hydroxychloroquine and levothyroxine

Hydroxychloroquine sulfate tablets (Fenle, 0.1g) will be given at a total daily dose of 0.2g to 0.4g based on individual weight as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.

DRUG

Levothyroxine

Levothyroxine sodium tablets (Euthyrox, 50 μg) will be given 12.5μg \~50 μg daily based on patients' TSH levels and weights as described above. During the study, if TSH is higher than 4.0 mIU/L or exceeds the lower limit of the reference range of the center in the first trimester, or TSH level exceeds the normal range of the center during the second or the third trimester, subjects will be instructed to suspend the medication and visit the Department of Endocrinology.

Trial Locations (2)

510000

RECRUITING

Sun Yat-Sen Memorial Hospital, Guangzhou

510120

NOT_YET_RECRUITING

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER